Recent advances in retrometabolic drug design (RMDD) and development.
As a general review for the 7th Retrometabolism-Based Drug Design and Targeting Conference, recent developments within this field are briefly reviewed with various illustrative examples from different therapeutic areas. Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs and of chemical delivery systems (CDS). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and structure-metabolism relationships; however, they achieve it by different means: whereas soft drugs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps.
Bodor
N
N
Center for Drug Discovery, University of Florida, Gainesville, FL 32610-0497, USA. nsbodor@gmail.com
Buchwald
P
P
D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D055432:Metabolomics